Pharmaxis Ltd (AU:SNT) has released an update.
Syntara Limited has announced a virtual investor briefing on April 30, 2024, to discuss its quarterly progress and upcoming plans, including its clinical drug development for blood cancers and fibrotic diseases. The event will feature CEO Gary Phillips and offers a Q&A session, with registration available online. The company, known for its expertise in amine oxidase chemistry, is currently managing multiple clinical studies and has existing respiratory products generating royalties.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
